AstraZeneca Stock Forecast, Price & News

AstraZeneca's stock was trading at $44.58 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, AZN stock has increased by 26.6% and is now trading at $56.45.
View which stocks have been most impacted by COVID-19.

10 Wall Street analysts have issued "buy," "hold," and "sell" ratings for AstraZeneca in the last year. There are currently 3 sell ratings, 2 hold ratings and 5 buy ratings for the stock, resulting in a consensus recommendation of "Hold."
View analyst ratings for AstraZeneca.

AstraZeneca is scheduled to release its next quarterly earnings announcement on Thursday, October 22nd 2020.
View our earnings forecast for AstraZeneca.

AstraZeneca plc (NYSE:AZN) posted its earnings results on Thursday, July, 30th. The company reported $0.48 earnings per share for the quarter, topping the Thomson Reuters' consensus estimate of $0.44 by $0.04. The firm earned $6.28 billion during the quarter, compared to analyst estimates of $6.27 billion. AstraZeneca had a return on equity of 37.72% and a net margin of 8.36%. The business's revenue for the quarter was up 9.7% on a year-over-year basis. During the same period in the previous year, the company earned $0.73 earnings per share.
View AstraZeneca's earnings history.

AstraZeneca announced a semi-annual dividend on Friday, July 31st. Investors of record on Friday, August 14th will be paid a dividend of $0.45 per share on Monday, September 14th. This represents a dividend yield of 2.5%. The ex-dividend date of this dividend is Thursday, August 13th.
View AstraZeneca's dividend history.

Shares of AstraZeneca split before market open on Monday, July 27th 2015. The 2-1 split was announced on Friday, June 26th 2015. The newly created shares were issued to shareholders after the market closes on Friday, July 24th 2015. An investor that had 100 shares of AstraZeneca stock prior to the split would have 200 shares after the split.

10 equities research analysts have issued twelve-month price objectives for AstraZeneca's stock. Their forecasts range from $60.00 to $65.00. On average, they expect AstraZeneca's stock price to reach $61.67 in the next twelve months. This suggests a possible upside of 9.2% from the stock's current price.
View analysts' price targets for AstraZeneca.

News headlines about AZN stock have been trending somewhat negative this week, according to InfoTrie Sentiment Analysis. The research group scores the sentiment of media coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. AstraZeneca earned a news sentiment score of -1.6 on InfoTrie's scale. They also assigned news headlines about the company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an effect on the company's share price in the next few days.
View the latest news about AstraZeneca.

AstraZeneca saw a decrease in short interest in August. As of August 31st, there was short interest totaling 4,130,000 shares, a decrease of 37.2% from the August 15th total of 6,580,000 shares. Based on an average daily volume of 6,690,000 shares, the short-interest ratio is presently 0.6 days.
View AstraZeneca's Short Interest.

Some companies that are related to AstraZeneca include Johnson & Johnson (JNJ), Roche Holdings AG Basel (RHHBY), Merck & Co., Inc. (MRK), Novartis (NVS), Pfizer (PFE), Abbott Laboratories (ABT), Novo Nordisk A/S (NVO), AbbVie (ABBV), Eli Lilly And Co (LLY), Bristol-Myers Squibb (BMY), Sanofi (SNY), GlaxoSmithKline (GSK), Commonwealth Bank of Australia (CSLLY), Celgene (CELG) and Zoetis (ZTS).
View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other AstraZeneca investors own include Pfizer (PFE), Gilead Sciences (GILD), Johnson & Johnson (JNJ), Moderna (MRNA), NVIDIA (NVDA), AbbVie (ABBV), Tesla (TSLA), AT&T (T), Advanced Micro Devices (AMD) and Alibaba Group (BABA).

AstraZeneca trades on the New York Stock Exchange (NYSE) under the ticker symbol "AZN."

AstraZeneca's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include FMR LLC (1.82%), Jennison Associates LLC (1.49%), Fisher Asset Management LLC (0.64%), GQG Partners LLC (0.35%), Bank of America Corp DE (0.32%) and Winslow Capital Management LLC (0.23%).
View institutional ownership trends for AstraZeneca.

AZN stock was sold by a variety of institutional investors in the last quarter, including CIBC Private Wealth Group LLC, FMR LLC, Winslow Capital Management LLC, Assetmark Inc., Cidel Asset Management Inc., Russell Investments Group Ltd., Charles Schwab Investment Management Inc., and Hardman Johnston Global Advisors LLC.
View insider buying and selling activity for AstraZeneca.

AZN stock was purchased by a variety of institutional investors in the last quarter, including GQG Partners LLC, Two Sigma Advisers LP, Stifel Financial Corp, Fisher Asset Management LLC, Jennison Associates LLC, Avidity Partners Management LP, Nuveen Asset Management LLC, and Bank of America Corp DE.
View insider buying and selling activity for AstraZeneca.

Shares of AZN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of AZN stock can currently be purchased for approximately $56.45.

AstraZeneca has a market capitalization of $148.15 billion and generates $24.38 billion in revenue each year. The company earns $1.34 billion in net income (profit) each year or $1.75 on an earnings per share basis. AstraZeneca employs 70,600 workers across the globe.

The official website for AstraZeneca is www.astrazeneca.com.

AstraZeneca's mailing address is 1 FRANCIS CRICK AVENUE CAMBRIDGE BIOMEDICAL CAMPUS, CAMBRIDGE X0, CB2 0AA. The company can be reached via phone at 44-20-3749-5000 or via email at [email protected]